These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27812199)

  • 21. Generation of two LRRK2 homozygous knockout human induced pluripotent stem cell lines using CRISPR/Cas9.
    Chen S; Luo Z; Ward C; Ibañez DP; Liu H; Zhong X; Sharma NK; Qin B; Fan W; Wang D
    Stem Cell Res; 2020 May; 45():101804. PubMed ID: 32339904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Age-related pathology after adenoviral overexpression of the leucine-rich repeat kinase 2 in the mouse striatum.
    Kritzinger A; Ferger B; Gillardon F; Stierstorfer B; Birk G; Kochanek S; Ciossek T
    Neurobiol Aging; 2018 Jun; 66():97-111. PubMed ID: 29550548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation of an induced pluripotent stem cell line (DANi-011A) from a Parkinson's disease patient with a LRRK2 p.G2019S mutation.
    Chen M; Maimaitili M; Buchholdt SH; Jensen UB; Febbraro F; Denham M
    Stem Cell Res; 2020 May; 45():101781. PubMed ID: 32305865
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Kim J; Daadi EW; Daadi ES; Oh T; Deleidi M; Daadi MM
    Cells; 2023 Oct; 12(21):. PubMed ID: 37947628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neural Stem Cells of Parkinson's Disease Patients Exhibit Aberrant Mitochondrial Morphology and Functionality.
    Walter J; Bolognin S; Antony PMA; Nickels SL; Poovathingal SK; Salamanca L; Magni S; Perfeito R; Hoel F; Qing X; Jarazo J; Arias-Fuenzalida J; Ignac T; Monzel AS; Gonzalez-Cano L; Pereira de Almeida L; Skupin A; Tronstad KJ; Schwamborn JC
    Stem Cell Reports; 2019 May; 12(5):878-889. PubMed ID: 30982740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The LRRK2-G2019S mutation attenuates repair of brain injury partially by reducing the release of osteopontin-containing monocytic exosome-like vesicles.
    An J; Yang H; Park SM; Chwae YJ; Joe EH
    Neurobiol Dis; 2024 Jul; 197():106528. PubMed ID: 38740348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of induced pluripotent stem cells (IBMSi011-A) from a patient with Parkinson's disease carrying LRRK2 p.I1371V mutation.
    Lin HI; Cheng YC; Ko HW; Wen CH; Lu HE; Huang CY; Hsieh PCH; Lin CH
    Stem Cell Res; 2019 May; 37():101447. PubMed ID: 31029016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The parkinson's disease-associated LRRK2 mutation R1441G inhibits neuronal differentiation of neural stem cells.
    Bahnassawy L; Nicklas S; Palm T; Menzl I; Birzele F; Gillardon F; Schwamborn JC
    Stem Cells Dev; 2013 Sep; 22(18):2487-96. PubMed ID: 23600457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation of induced pluripotent stem cells (NIMHi001-A) from a Parkinson's disease patient of East Indian ethnicity carrying LRRK2 I1371V variant.
    Datta I; Sowmithra ; Jagtap S; Potdar C; Yadav R; Pal P
    Stem Cell Res; 2020 Apr; 44():101768. PubMed ID: 32244201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Wild-type and mutant (G2019S) leucine-rich repeat kinase 2 (LRRK2) associate with subunits of the translocase of outer mitochondrial membrane (TOM) complex.
    Neethling A; Engelbrecht L; Loos B; Kinnear C; Theart R; Abrahams S; Niesler T; Mellick GD; Williams M; Bardien S
    Exp Cell Res; 2019 Feb; 375(2):72-79. PubMed ID: 30597143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The multifaceted role of LRRK2 in Parkinson's disease: From human iPSC to organoids.
    Oun A; Sabogal-Guaqueta AM; Galuh S; Alexander A; Kortholt A; Dolga AM
    Neurobiol Dis; 2022 Oct; 173():105837. PubMed ID: 35963526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The dynamic switch mechanism that leads to activation of LRRK2 is embedded in the DFGψ motif in the kinase domain.
    Schmidt SH; Knape MJ; Boassa D; Mumdey N; Kornev AP; Ellisman MH; Taylor SS; Herberg FW
    Proc Natl Acad Sci U S A; 2019 Jul; 116(30):14979-14988. PubMed ID: 31292254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reprogramming of a human induced pluripotent stem cell (iPSC) line from a Parkinson's disease patient with a R1628P variant in the LRRK2 gene.
    Ma D; Zhou W; Ng EY; Zeng L; Zhao Y; Tan EK
    Stem Cell Res; 2017 Jan; 18():45-47. PubMed ID: 28395802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of LRRK2 in the regulation of dopamine receptor trafficking.
    Rassu M; Del Giudice MG; Sanna S; Taymans JM; Morari M; Brugnoli A; Frassineti M; Masala A; Esposito S; Galioto M; Valle C; Carri MT; Biosa A; Greggio E; Crosio C; Iaccarino C
    PLoS One; 2017; 12(6):e0179082. PubMed ID: 28582422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
    Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
    Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LRRK2 in peripheral and central nervous system innate immunity: its link to Parkinson's disease.
    Lee H; James WS; Cowley SA
    Biochem Soc Trans; 2017 Feb; 45(1):131-139. PubMed ID: 28202666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generation of a human iPSC line (CIBi014-A) from a patient with Parkinson's disease carrying a novel heterozygotic PARK8 (LRRK2) mutation.
    Li L; Si X; Yang J; Lei M; Liu H; Ruan J; Fu H; Li W; Yang H; Lei X; Sang H
    Stem Cell Res; 2023 Feb; 66():102995. PubMed ID: 36528012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in matrix metalloprotease activity and progranulin levels may contribute to the pathophysiological function of mutant leucine-rich repeat kinase 2.
    Caesar M; Felk S; Zach S; Brønstad G; Aasly JO; Gasser T; Gillardon F
    Glia; 2014 Jul; 62(7):1075-92. PubMed ID: 24652679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in Stability, Activity and Mutation Effects Between Human and Mouse Leucine-Rich Repeat Kinase 2.
    Langston RG; Rudenko IN; Kumaran R; Hauser DN; Kaganovich A; Ponce LB; Mamais A; Ndukwe K; Dillman AA; Al-Saif AM; Beilina A; Cookson MR
    Neurochem Res; 2019 Jun; 44(6):1446-1459. PubMed ID: 30291536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.